INTRODUCTION
One of the problems associated with oral sustained release systems is that they do not remain for long in the upper gastrointestinal tract (GIT) which is the main absorption region for most drugs. Thus, rapid gastrointestinal transit can prevent complete drug release in the absorption zone and this may lead to reduction in drug bioavailability and efficacy of administered dose [1] . However, the development of gastroretentive drug delivery systems (GRDDS) can overcome this problem. GDDS are capable of being retained in the stomach for a long period of time while they release the drug in a sustained manner for continuous delivery to its absorption site in the upper GIT [2] .
Various approaches have been employed to increase the retention of oral dosage forms in the stomach. One of the most common approaches is to formulate floating drug delivery systems (FDDS) [3] . FDDS have a bulk density lower than gastric fluids and thus remain buoyant in the stomach without affecting the gastric emptying time for a prolonged time [4] .
Bupropion is a atypical antidepressant widely used in major depressive disorders and smoking recession [5] . In the treatment of depression, multiple dosing is required. Many of its adverse effects are dose-dependent, and hence a prolonged-release dosage form would improve patient compliance and tolerability. Moreover, it is expected that a gastroretentive dosage form of bupropion HCl would provide more predictable bioavailability and better control of the fluctuations in drug plasma concentrations.
The objective of the present study was to develop bupropion HCl floating matrix tablets for prolonged retention and drug release in the stomach, as well as for improved drug availability and reduced fluctuation of the drug in plasma.
EXPERIMENTAL Materials
Bupropion HCl (Eczacibazsi, Turkey) and HPMC (Methocel K4M, K15M Colorcon, England) were used as drug and matrix former, respectively..NaCMC (3000 cps), lactose, tricalcium phosphate, polyvinylpyrrolidone K-10, sodium bicarbonate and magnesium stearate were all obtained from Merck, Germany. Microcrystalline cellulose (Avicel PH 102) was produced by FMC Corporation.
Preparation and characterization of matrix tablets
Matrix tablets containing 150 mg bupropion HCl powder along with various amounts of HPMC K4M, HPMC 15M or NaCMC plus fillers (MCC, lactose and tricalcium phosphate) were prepared (as per the compositions in Tables 1 and 2) by compression in a single-punch tablet machine (Erweka, Germany) equipped with 12 mm flat-faced punches. Since bupropion HCl shows poor compressibility and flowability, wet granulation was used to prepare the tablets. For this purpose, ethanol 96 %v/v was employed as the granulation fluid while polyvinylpyrrolidone (PVP K10 was the binder. The other ingredients added to the formulation are sodium bicarbonate as gas-generating agent and magnesium stearate as lubricant. To prepare the tablets, bupropion HCl was mixed with all the ingredients, except magnesium stearate, in a mortar. Next, alcohol solution of PVP (10 %w/v) was added dropwise until a suitable mass for granulation was obtained, after which the wet mass was granulated through a 707 µm aperture sieve. The granules obtained were dried in an oven at 40 ˚C for 1 h, passed through a 595 µm aperture sieve, blended with 0.5 % magnesium stearate and then compressed into tablets of approximately 400 mg each and hardness of 6 -8 kP. Tablet friability was determined using 15 tablets from each formulation in an Erweka TA Roche-type friabilitor at a speed of 25 rpm for 4 min. The hardness of 10 tablets was evaluated with an Erweka TBH 28 hardness tester, while the mean thickness of 10 tablets was measured using a caliper.
In vitro buoyancy studies
In vitro buoyancy of the tablets was determined by measuring floating lag time and duration of floating, according to the method described by Rosa et al [6] . In this method, one tablet was placed in a beaker containing 100 ml of 0.1M HCl. The time required for the tablet to rise to the surface was considered as the floating lag time. The total time that the tablet remained floating on the surface was also taken as duration of floating. These tests were carried out on 5 tablets per formulation.
In vitro dissolution studies
Drug release studies were performed on only the formulations that show suitable floating behavior. The test carried out in 900 ml of 0.1M HCl using a dissolution tester (Erweka, Germany) USP 23 type 2 apparatus (paddle method), at 50 rpm and 37 ˚C. Samples (3 ml each) were taken hourly for 10 h while keeping the dissolution medium volume constant by replenishing the dissolution medium with an equivalent amount of fresh medium to that withdrawn. The samples were filtered through a 0.45 µm membrane filter (Whatman no. 1) and diluted to a suitable concentration with 0.1M HCl. The absorbance of the samples was measured at 252.5 nm using a Shimadzu UV-1201 spectrophotometer. Cumulative drug release was calculated from the calibration curve of the drug standard. The results were expressed as mean ± standard deviation (SD, n = 6). Ingredients A1  A2  A3  B1  B2  B3  C1  C2  C3  D1  D2  D3  E1  E2  F1  F2  HPMC  K4M  60  80  100  60  80  100  60  80   HPMC  K15M  60  80  100  60  80  100 
Release kinetics
In order to determine drug release kinetics, the release data were fitted to various kinetic models -zero order [7] , first order [8] , Higuchi [9] and Hixon-Crowell [10] as shown in Eqs 1 -4, respectively. Q t = k 0 .t ………………………….…….
(1) where Q t is the % drug release at time t and K 0 is the release rate constant.
ln(100 ─ Q) = ln100 ─ k 1 .t ….…….. (2) where Q is % drug release and K 1 is release rate constant.
where Q is % drug release and K H is Higuchi release rate constant.
(100 ─ Q) 1/3 = 100 1/3 ─ K HC .t ……….. (4) where Q is % drug release and K HC is HixonCrowell rate constant. Furthermore, a simple semi-empirical model (Korsemeyer-Peppas) was used to determine the drug release mechanism for the matrix tablets systems [11] , as indicated in Eq 5.
log log log
where Q t is the amount of the released drug at time t, Q ∞ is the overall amount of drug (the whole dose), k kp is the constant incorporating the structural and geometric characteristics of the controlled release device, and n is the release exponent indicative of drug release mechanism. For cylindrical geometries such as tablets n = 0.45 corresponds to Fickian diffusion, 0.45 < n < 0.89 to non-Fickian (anomalous) diffusion and n = 0.89 to case 2 diffusion [12] .
In fitting data to the models, only points within the 10 -60 % drug release range were used, except for the Higuchi model where the range was 10 -70 %.
Statistical analysis
All the results were expressed as mean values ± standard deviation (SD). Singlefactor analysis of variance (ANOVA) with a Tukey post-hoc test, at 5 % significance level, was used to compare buoyancy and drug release data. The analyses were performed using SPSS 17.0 software.
RESULTS

Physical properties of bupropion tablets
The hardness of all the tablet formulations ranged from 6 -8 kP except for formulation G 1 which contained 54.5 % NaCMC that exhibited a hardness of 5.3 kP. The friability of the tablets were within USP 23 limits [13] , being < 1 %. The thickness of the tablets ranged from 3.10 -3.64 mm.
Buoyancy of tablets
Buoyancy data are presented in Tables 3 and  4 . The results from buoyancy studies on formulation batch series G showed that by increasing the amount of NaCMC and decreasing the amount of MCC, the time required for the tablets to float increased while the duration of floating decreased (p < 0.05). Formulation G 1 which did not contain MCC did not float at all while formulation G 4 which had the lowest concentration of NaCMC floated rapidly; however, due to the low concentration of polymer it disintegrated soon after floatation. In case of formulation series H, increasing HPMC K4M: NaCMC ratio has caused the tablets to float more quickly (p < 0.05). Formulation H 1 with the highest amount of NaCMC floated for only 3 h. Raising the amount of HPMC reduced drug release rate (p < 0.05). Formulation series B The release profile of bupropion HCl from tablets containing varying ratios of HPMC K4M and NaCMC as the matrix is shown in Figure 5 . The difference between drug release from matrices containing 2:3 and 3:1 ratios of HPMC K4M: NaCMC, i.e., formulations H 4 and H 2, was significant (p < 0.05) . 
Drug release profile
Release kinetics
The values of kinetic rate constant (k), determination coefficient (r 2 ) and release exponent (n) are presented in Table 5 . The most appropriate model, based on the highest value of regression coefficient (r 
DISCUSSION
All the formulations had good physical properties. The low hardness of formulation G 1 is due to the absence of MCC. The good floating ability of formulations series A, B, C and D is a result of the evolution of CO 2 when sodium bicarbonate interacts with the dissolution medium which is acidic. Consequently entrapment of the gas (CO 2 ) inside the hydrated polymeric matrix lowers the density of the tablet and thus causes the dosage form to float.
Increasing the amount of polymer in the formulations prepared with MCC did not influence floating lag time of the tablets significantly. However, in formulations containing lactose, floating lag time increased when the content of HPMC was raised to 100 mg. This may be attributed to the structural properties of MCC including swellable and porous structure and also low density of particles [14] [15] [16] . MCC gave such good floating properties to the formulations that increasing the polymer to sodium bicarbonate ratio in formulation series A and B did not increase floating lag time substantially. In contrast, increasing the polymer content to 100 mg in formulation series C and D, where lactose was used in place of MCC, led to increase in floating lag time due to higher water absorption by the polymer making the matrix denser.
Formulation series E and F did not float due to the insoluble nature of tricalcium phosphate which also imparted low porosity to the tablet matrix. Furthermore, the high density of tricalcium phosphate would also have enhanced the overall tablet density to a level above that of the simulated gastric fluid with the result that the tablets failed to float throughout the test period.
Formulation series G prepared with NaCMC did not show good floating properties because NaCMC is a hydrophilic polymer with a high water absorption capacity and therefore, the tablets were weighed down in the medium by the absorbed fluid. Moreover, the gel layer formed by the polymer seems to be lower in strength than that formed by HPMC and, therefore, could not entrap the evolved gas efficiently. This is why increasing the proportion of NaCMC in its mixture with HPMC K4M (formulation series H), resulted in high floating lag time before the tablets floated.
The reduction in drug release rate as polymer (HPMC) content or viscosity increased may be attributed to stronger gel formation. Highly viscous gels cause retardation of drug release [17, 18] . Burst effect was observed in all the formulations due to rapid drug dissolution from the surface of the tablets. This effect was more pronounced at lower polymer concentrations. Furthermore, formulations containing MCC exhibited greater burst effect than those containing lactose, especially at a low polymer concentration (15 %) because of the disintegrating and swelling properties of former. Subsequently, drug release from the tablets containing lactose accelerated over that from tablets formulated with MCC which is insoluble and therefore might have hindered drug release from the tablets. Increase in the proportion of HPMC K4M relative to that of NaCMC led to slower drug release because HPMC has capacity to form a more stable gel than NaCMC.
When the release data were fitted to various kinetic models, the lowest regression coefficient (r Generally, the n values from the KorsemeyerPeppas relationship for all the formulations were > 0.45 which is indicative of drug release mechanism based on diffusion, swelling and erosion. Increasing the relative proportion of the polymer yielded higher n values, especially for formulation series of A and B. For both series, drug release at lower polymer contents was mainly governed by diffusion, while at higher polymer contents, the release mechanism shifted to anomalous transport with both diffusion and erosion controlling release.
CONCLUSION
Floating tablets of bupropion HCl were successfully developed in this study. HPMC is a matrix material for designing floating tablets and appropriate blending with NaCMC can yield floating tablets with suitable drug release and swelling characteristics. However, further studies, including in vivo investigations, are necessary to confirm the findings of this work.
